Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Antibacterial Toxin-Derived Immunotoxins: Innovative Constructs for Targeted Breast Cancer Treatment

Document Type : Original Article

Authors

Mona Maleknejadyazdi 1
Ali Akbar Haddad-Mashadrizeh 2

1 Advanced computational center, Khayyam Innovation Ecosystem, Mashhad, Iran

2 Department of Molecular and Cell Biology, Institute of Biotechnology, and Department of Ferdowsi University of Mashhad, Iran

https://doi.org/10.22034/pmj.2024.2031780.1040
Abstract
Cancer remains one of humanity's leading causes of both illness and death globally. In women worldwide, breast cancer remains the most widespread malignant condition. The new possibilities for direct treatment offered by the advances made thereby were the subject of the recent study undertaken as it sought to unravel tumorigenesis through genetics and molecular appreciation of cancer. Specifically, this research centers on devising and testing immunotoxins as anti-bacterial toxin-based constructs to treat breast cancer. These immunotoxins can kill cancer cells selectively while leaving normal tissues unharmed as they bind only to cancer cell antigens by using both the specificity of antibodies and bacterial toxins' cytotoxicity power. We assessed immunotoxins' binding affinities to their respective antigens based on computational dockings like HADDOCK explaining encouraging results characterized by good docking scores accompanied by low RMSDs—also, dual targeting approaches combined with structure-based. By developing humanized antibodies and novel targeting moieties, challenges such as immunogenicity and non-specific toxicity have been tackled. Our findings suggest that optimized immunotoxins
have great potential to enhance therapeutic window as well as efficacy in cancer treatments

Keywords

Breast Cancer
Immunotoxins
Targeted Therapy
Binding Affinity
Computational Docking

Subjects

  1. Maleknejadyazdi, M. and A.A. Haddad-Mashadrizeh, Designing and Simulating the Structure of an Effective Immunotoxin in Breast Cancer. Personalized Medicine Journal, 2023. 8(31): p. 10-25.
  2. Vogelstein, B. and K.W. Kinzler, The multistep nature of cancer. Trends in genetics, 1993. 9(4): p. 138-141.
  3. Vogelstein, B. and K.W. Kinzler, Cancer genes and the pathways they control. Nature medicine, 2004. 10(8): p. 789-799.
  4. Stratton, M.R., P.J. Campbell, and P.A. Futreal, The cancer genome. Nature, 2009. 458(7239): p. 719-724.
  5. Harbeck, N., et al., Breast cancer. Nature reviews Disease primers 5: 66. 2019.
  6. Murali, B., et al., Treatment of HR+/HER2− breast cancer in urban mainland China: Results from the CancerMPact Survey 2019. Breast Cancer Research and Treatment, 2022. 195(3): p. 441-451.
  7. Loibl, S., et al., Epidemiology and risk factors. Breast Cancer. Lancet, 2021. 397: p. 1750-1769.
  8. Clancy, E., ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline. Renal & Urology News, 2023: p. NA-NA.
  9. Ferlay, J., et al., Cancer statistics for the year 2020: An overview. International journal of cancer, 2021. 149(4): p. 778-789.
  10. Nia, H.T., L.L. Munn, and R.K. Jain, Physical traits of cancer. Science, 2020. 370(6516): p. eaaz0868.
  11. Galon, J. and D. Bruni, Tumor immunology and tumor evolution: intertwined histories. Immunity, 2020. 52(1): p. 55-81.
  12. Mathew, M. and R.S. Verma, Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer science, 2009. 100(8): p. 1359-1365.
  13. Kreitman, R.J. and I. Pastan, Immunotoxins for targeted cancer therapy. Advanced drug delivery reviews, 1998. 31(1-2): p. 53-88.
  14. Amoozadeh, S., et al., Preparation of diphtheria and pseudomonas exotoxin a immunotoxins and evaluation of their cytotoxicity effect on SK-BR-3, BT-474, and MDA-MB-231 breast cancer cell lines. Cancer investigation, 2019. 37(10): p. 546-557.
  15. Akbari, B., et al., Immunotoxins in cancer therapy: Review and update. International reviews of immunology, 2017. 36(4): p. 207-219.
  16. Havaei, S.M., M.G. Aucoin, and A. Jahanian-Najafabadi, Pseudomonas exotoxin-based immunotoxins: over three decades of efforts on targeting cancer cells with the toxin. Frontiers in Oncology, 2021. 11: p. 781800.
  17. Reiter, Y., Recombinant immunotoxins in targeted cancer cell therapy. 2001.
  18. Li, Y.M. and W.A. Hall, Targeted toxins in brain tumor therapy. Toxins, 2010. 2(11): p. 2645-2662.
  19. Dieffenbach, M. and I. Pastan, Mechanisms of resistance to immunotoxins containing pseudomonas exotoxin a in cancer therapy. Biomolecules, 2020. 10(7): p. 979.
  20. Ambrosetti, F., et al., Modeling antibody-antigen complexes by information-driven docking. Structure, 2020. 28(1): p. 119-129. e2.
  21. Walls, P.H. and M.J. Sternberg, New algorithm to model protein-protein recognition based on surface complementarity: Applications to antibody-antigen docking. Journal of molecular biology, 1992. 228(1): p. 277-297.
  22. Li, C.H., et al., A soft docking algorithm for predicting the structure of antibody‐antigen complexes. Proteins: Structure, Function, and Bioinformatics, 2003. 52(1): p. 47-50.
  23. Lázaro-Gorines, R., et al., A novel carcinoembryonic antigen (CEA)-targeted trimeric immunotoxin shows significantly enhanced antitumor activity in human colorectal cancer xenografts. Scientific Reports, 2019. 9(1): p. 11680.
  24. Du, X., et al., Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity. Cancer research, 2008. 68(15): p. 6300-6305.
  25. Desta, I.T., et al., Mapping of antibody epitopes based on docking and homology modeling. Proteins: Structure, Function, and Bioinformatics, 2023. 91(2): p. 171-182.
Personalized and Precision Medicine Journal
Volume 9, Issue 34
Original article
Summer 2024
Pages 27-34

  • Receive Date 04 May 2024
  • Revise Date 14 July 2024
  • Accept Date 25 August 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us